EUCTR2010-023575-25-DE进行中（未招募）不适用
Perioperative FOLFOXIRI and bevacizumab compared with postoperative FOLFOX in patients with resectable liver metastases from colorectal cancer (PERIMAX). - PERIMAX
niversität Regensburg0 个研究点开始时间: 2011年12月22日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Histological proven CRC with completely resectable metachronous or synchronous liver metastases (as judged by the treating surgeon).
- •-Patients must have undergone complete resection (R0) of the primary tumor at least 4 weeks before randomization. Or in case of synchronous disease with intact primary; the primary tumor have to be R0 resectable together with the liver metastases and the patient has a non-obstructive primary tumor and is able to receive preoperative chemotherapy before surgery. Synchronous rectal primary is not allowed.
- •-Measurable hepatic disease by Response Evaluation Criteria in Solid Tumors (RECIST version 1.1).
- •-Ability to undergo anaesthesia and hepatic resection.
- •-Patients must be from 18 to 75 years.
- •-ECOG Performance status = 1
- •-Previous adjuvant oxaliplatin-containing chemotherapy for primary CRC is allowed, if completed at least 12 months before inclusion in this study.
- •-All the following tests should be done within 4 weeks prior to randomization
- •a. Absolute neutrophil count > 1.5 x 109/L, platelets > 100 x 109/L, and hemoglobin > 9 g/dL or 5.59 mmol/l.
- •b. Serum creatinine less than 1.5 times the upper limit of normal (ULN) (to exclude severe renal impairment); no significant proteinuria (urine dipstick for proteinuria ³ 2+. If urine dipstick is ³ 2+, 24-hour urine must demonstrate £ 1 g of protein in 24 hours for patient to be eligible).
- •c. Absence of major hepatic insufficiency (bilirubin < 1.5 x ULN and aspartate aminotransferase (ASAT)/alanine aminotransferase (ALAT) < 5 x ULN).
- •d. Patients not receiving therapeutic anticoagulation must have an INR < 1.5 ULN and aPTT < 1.5 ULN within 7 days prior to registration. The use of full dose anticoagulants is allowed as long as the INR or aPTT is within therapeutic limits (according to the medical standard in the institution) and the patient has been on a stable dose for anticoagulants for at least two weeks at the time of registration.
- •- Negative serum pregnancy test within 7 days of starting study treatment in pre-menopausal women and women < 1 year after the onset of menopause is required before entering in the trial. Note: a negative test has to be reconfirmed by a urine test, should the 7-day window be exceeded.
- •-Adequate contraception is required during and for 3 months after study treatment for both male and female patients if the risk of conception exists.
- •-Signed written informed consent before randomization according to ICH/EU GCP, and local, national and international regulations.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 120
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
- •-Histological proven CRC with completely resectable metachronous or synchronous liver metastases (as judged by the treating surgeon).
- •-Patients must have undergone complete resection (R0) of the primary tumor at least 4 weeks before randomization. Or in case of synchronous disease with intact primary; the primary tumor have to be R0 resectable together with the liver metastases and the patient has a non-obstructive primary tumor and is able to receive preoperative chemotherapy before surgery. Synchronous rectal primary is not allowed.
- •-Measurable hepatic disease by Response Evaluation Criteria in Solid Tumors (RECIST version 1.1).
- •-Ability to undergo anaesthesia and hepatic resection.
- •-Patients must be from 18 to 75 years.
- •-ECOG Performance status = 1
- •-Previous adjuvant oxaliplatin-containing chemotherapy for primary CRC is allowed, if completed at least 12 months before inclusion in this study.
- •-All the following tests should be done within 4 weeks prior to randomization
- •a. Absolute neutrophil count > 1.5 x 109/L, platelets > 100 x 109/L, and hemoglobin > 9 g/dL or 5.59 mmol/l.
- •b. Serum creatinine less than 1.5 times the upper limit of normal (ULN) (to exclude severe renal impairment); no significant proteinuria (urine dipstick for proteinuria ³ 2+. If urine dipstick is ³ 2+, 24-hour urine must demonstrate £ 1 g of protein in 24 hours for patient to be eligible).
- •c. Absence of major hepatic insufficiency (bilirubin < 1.5 x ULN and aspartate aminotransferase (ASAT)/alanine aminotransferase (ALAT) < 5 x ULN).
- •d. Patients not receiving therapeutic anticoagulation must have an INR < 1.5 ULN and aPTT < 1.5 ULN within 7 days prior to registration. The use of full dose anticoagulants is allowed as long as the INR or aPTT is within therapeutic limits (according to the medical standard in the institution) and the patient has been on a stable dose for anticoagulants for at least two weeks at the time of registration.
- •- Negative serum pregnancy test within 7 days of starting study treatment in pre-menopausal women and women < 1 year after the onset of menopause is required before entering in the trial. Note: a negative test has to be reconfirmed by a urine test, should the 7-day window be exceeded.
- •-Adequate contraception is required during and for 3 months after study treatment for both male and female patients if the risk of conception exists.
- •-Signed written informed consent before randomization according to ICH/EU GCP, and local, national and international regulations.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 120
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- •- Evidence of extra-hepatic metastasis of CRC.
- •- Previous chemotherapy for metastatic disease. Radiotherapy alone is allowed if given pre or post protocol treatment.
- •- Pregnancy or breast feeding
- •- Major surgical procedure, open biopsy, or significant traumatic injury within 4 weeks prior to randomization.
- •- Previous exposure to VEGF/VEGFR-targeting therapy within the last 12 months.
- •- Treatment with any other investigational agent, or participation in another clinical trial within 30 days prior to entering this study.
- •- Past or current history (within the last 2 years prior to treatment start) of other malignancies except metastatic colorectal cancer (patients with curatively treated basal and squamous cell carcinoma of the skin or in situ carcinoma of the cervix are eligible).
- •- Thrombosis or severe bleeding within 6 months prior to entry into the study (except for bleeding of the tumor before its surgical resection) and no evidence of bleeding diathesis or coagulopathy.
- •- Peripheral neuropathy NCI CTCAE-grade = 1, active inflammatory bowel disease or other bowel disease causing chronic diarrhea (defined as > 4 loose stools per day), serious wound complications, ulcers, or bone fractures.
- •- History of interstitial lung disease (eg, pneumonitis or pulmonary fibrosis) hemoptoe or evidence of interstitial lung disease on baseline chest X-ray or CT scan.
- •- Clinically significant cardiovascular disease, including: uncontrolled hypertension, New York Heart Association (NYHA) class II-IV heart failure, unstable angina pectoris within the past 12 months, peripheral vascular disease = grade 2, serious cardiac arrhythmia requiring medication, myocardial infarction within the past 12 months, cerebrovascular accident or transient ischemic attack within the past 12 months, other clinically significant cardiovascular disease.
- •- Evidence of any other disease, metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or puts the patient at high risk for treatment-related complications.
- •- Known hypersensitivity or contraindication to the drugs used in the trial (eg: 5-FU, folinic acid/ leucovorin, oxaliplatin, bevacizumab, irinotecan)
- •- Concomitant treatment with ASS > 325 mg or NSAIDs, known to inhibit platelet function, sorivudin or analog compounds or preparations of St. John’s wort
- •- Evidence of extra-hepatic metastasis of CRC.
- •- Previous chemotherapy for metastatic disease. Radiotherapy alone is allowed if given pre or post protocol treatment.
- •- Pregnancy or breast feeding
- •- Major surgical procedure, open biopsy, or significant traumatic injury within 4 weeks prior to randomization.
- •- Previous exposure to VEGF/VEGFR-targeting therapy within the last 12 months.
- •- Treatment with any other investigational agent, or participation in another clinical trial within 30 days prior to entering this study.
- •- Past or current history (within the last 2 years prior to treatment start) of other malignancies except metastatic colorectal cancer (patients with curatively treated basal and squamous cell carcinoma of the skin or in situ carcinoma of the cervix are eligible).
- •- Thrombosis or severe bleeding within 6 months prior to entry into the study (except for bleeding of the tumor before its surgical resection) and no evidence of bleeding diathesis or coagulopathy.
- •- Peripheral neuropathy NCI CTCAE-grade = 1, active inflammatory bowel disease or other bowel disease causing chronic diarrhea (defined as > 4 loose stools per day), serious wound complications, ulcers, or bone fractures.
- •- History of interstitial lung disease (eg, pneumonitis or pulmonary fibrosis) hemoptoe or evidence of interstitial lung disease on baseline chest X-ray or CT scan.
- •- Clinically significant cardiovascular disease, including: uncontrolled hypertension, New York Heart Association (NYHA) class II-IV heart failure, unstable angina pectoris within the past 12 months, peripheral vascular disease = grade 2, serious cardiac arrhythmia requiring medication, myocardial infarction within the past 12 months, cerebrovascular accident or transient ischemic attack within the past 12 months, other clinically significant cardiovascular disease.
- •- Evidence of any other disease, metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or puts the patient at high risk for treatment-related complications.
- •- Known hypersensitivity or contraindication to the drugs used in the trial (eg: 5-FU, folinic acid/ leucovorin, oxaliplatin, bevacizumab, irinotecan)
- •- Concomitant treatment with ASS > 325 mg or NSAIDs, known to inhibit platelet function, sorivudin or analog compounds or preparations of St. John’s wort
研究者
相似试验
撤回
2 期
Perioperative Treatment of Resectable Liver MetastasesColon Cancer Liver MetastasisNCT01540435University of Regensburg
已完成
不适用
Efficacy and Safety of FOLFOXIRI plus Bevacizumab and Doublet plus Biologics in Patients With Previously Untreated BRAF V600E-mutant Metastatic Colorectal Cancer: A Multi-institutional retrospective study (WJOG13219G)BRAF V600E-mutant Metastatic Colorectal CancerJPRN-UMIN000041098West Japan Oncology Group250
已完成
2 期
Safety and efficacy of FOLFOX plus bevacizumab or FOLFIRI plus bevacizumab as second line Therapy in Advanced colorectal Cancer previously treated with bevacizumab.JPRN-UMIN000002378Japan South West Oncology Group45
已完成
2 期
Response Rate of Bevacizumab and FOLFOXIRI with pegfilgrastim in RAS-mutant type unresectable metastatic colorectal cancer.JPRN-UMIN000018187Kyoto University Hospital40
进行中（未招募）
不适用
patients with colorectal carcinoma compared to patients with normal LDH serum levelspatients treated with first-line chemotherapy and bevacizumab will be prospectively stratified according to LDH serum levelsEUCTR2012-005048-46-ITFondazione GISCAD